Drug
Cemacabtagene Ansegedleucel
Cemacabtagene Ansegedleucel: highest development phase Phase 2, developed by Allogene Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Allogene Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| cemacabtagene ansegedleucel NCT06500273 | Phase 2 | Large B-cell Lymphoma |
Latest
No recent events.
Follow Cemacabtagene Ansegedleucel on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.